Evidence map›Paper›PMID 11161381›Full record

ArticleBritish journal of cancer2001

Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

S Zienolddiny, D Ryberg, M O Arab, V Skaug, A Haugen

Open access · bronzeAbstract read
In one paragraph

Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Role of DMP1 and its future in lung cancer diagnostics.Expert review of molecular diagnostics · 2008
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

S ZienolddinyDepartment of Toxicology, National Institute of Occupational Health, P.O. Box 8149 Dep., Oslo, N-0033, Norway.
D Ryberg
M O Arab
V Skaug
A Haugen
National Institute of Occupational Health · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinogenesis results from an accumulation of several genetic alterations. Mutations in the p53 gene are frequent and occur at an early stage of lung carcinogenesis. Loss of multiple chromosomal regions is another genetic alteration frequently found in lung tumours. We have examined the association between p53 mutations, loss of heterozygosity (LOH) at frequently deleted loci in lung cancer, and tobacco exposure in 165 tumours from non-small cell lung cancer (NSCLC) patients. A highly significant association between p53 mutations and deletions on 3p, 5q, 9p, 11p and 17p was found. There was also a significant correlation between deletions at these loci. 86% of the tumours with concordant deletion in the 4 most involved loci (3p21, 5q11-13, 9p21 and 17p13) had p53 mutations as compared to only 8% of the tumours without deletions at the corresponding loci (P< 0.0001). Data were also examined in relation to smoking status of the patients and histology of the tumours. The frequency of deletions was significantly higher among smokers as compared to non-smokers. This difference was significant for the 3p21.3 (hMLH1 locus), 3p14.2 (FHIT locus), 5q11-13 (hMSH3 locus) and 9p21 (D9S157 locus). Tumours with deletions at the hMLH1 locus had higher levels of hydrophobic DNA adducts. Deletions were more common in squamous cell carcinomas than in adenocarcinomas. Covariate analysis revealed that histological type and p53 mutations were significant and independent parameters for predicting LOH status at several loci. In the pathogenesis of NSCLC exposure to tobacco carcinogens in addition to clonal selection may be the driving force in these alterations.

Indexed as

ATP-Binding Cassette, Sub-Family C ProteinsLoss of HeterozygosityAdaptor Proteins, Signal TransducingAdenocarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCarrier ProteinsDNA AdductsDNA-Binding ProteinsDNA, NeoplasmFemaleHumansLung NeoplasmsMaleMicrosatellite RepeatsMiddle AgedAdaptor Proteins, Signal TransducingATP-Binding Cassette, Sub-Family C ProteinsCarrier ProteinsDNA AdductsDNA-Binding ProteinsDNA, NeoplasmMLH1 protein, humanMSH3 protein, humanmultidrug resistance-associated protein 1MutL Protein Homolog 1MutS Homolog 3 ProteinNeoplasm ProteinsNuclear ProteinsTumor Suppressor Protein p53

Identifiers

PMID11161381
PMCPMC2363705
OpenAlexW2084986598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.